Served as Head of Asia Regional Marketing and Chief of Korean Business Division

Santen Pharmaceutical Korea (hereinafter referred to as Santen Korea) announced on April 1 that it has appointed Jinhee Kim as its new Chief Executive Officer.

Santen Pharmaceutical Korea Appoints Jinhee Kim as New CEO View original image

CEO Kim joined Santen Korea in April 2008 as a marketing manager. In 2010, she led the establishment of Santen Korea's direct sales business model and drove the introduction of various new products, including a new drug for glaucoma.


She played a key role in laying a solid foundation for the early growth of the company's Korean business. She is recognized for successfully leading major strategic projects, such as the transfer of sales rights for MSD ophthalmology products and the exclusive distribution and promotion agreement for retinal products with Novartis Korea.


From 2019 to 2023, she oversaw marketing across the Asia region. After that, she was appointed as the head of the Korean business division and achieved results across both the Korean and Asian businesses.


CEO Jinhee Kim stated, "Based on the experience I have accumulated throughout my work in Korea and the wider Asian region, I will strive to create patient-centric value and achieve sustainable growth at the same time," adding, "Through close collaboration with employees, I will do my best to help Santen Pharmaceutical Korea make further strides as a trusted ophthalmology specialist company."



In this round of appointments, Santen Korea also newly appointed Hyemi Jung as head of the Strategic Division and Hyekyung Choi as head of the New Business Planning Division.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing